Biopeople

From Trainee to Senior Vice President

From Trainee to Senior Vice President

23.10.2012 - French Sartorius Stedim Biotech (Aubagne) has appointed Stefan Schlack as its new Senior Vice President of Marketing.

Schlack has been working for Sartorius since 1996. After completing vocational training in industrial business at the firm, he studied business economics and management in Cologne (GER) and worked in sales in its laboratory business unit. After taking his university degree in business management, Schlack relocated to the US, where he worked as a key account manager supporting pharmaceutical customers and handling OEM business. In 2006, he returned to Sartorius headquarters in Goetting. Since 2008, Stefan Schlack has been in charge of key account management as Vice President.

http://www.european-biotechnology-news.com/people/bio-people/2012-2/stefan-schlack.html

12.07.2012 In June, French Trophos SA appointed Christine Placet as its chief executive officer. She becomes CEO under a previously defined internal succession plan designed to provide continuity for Trophos, to bring the company's ongoing programmess to a successful conclusion and to seek strategic partnerships for its advanced clinical development drug candidates.

 From 2004, Placet was CFO of the clinical stage pharmaceutical company developing innovative therapeutics for indications with under-served needs in neurology and cardiology. She has over 25 years' experience in a variety of areas of finance and business management. Prior to joining Trophos, she was CFO in a number of growing companies and start-ups in various industries, and worked as an auditor for eight years for Ernst & Young. She has a graduate diploma in financial accounting (DESCF) and a business school diploma from Sup de Co Marseille (DESCAF). Damian Marron, previously CEO, has moved to the biopharmaceutical Company Cytheris SA.

01.08.2012 Antibody drug-conjugates specialist ADC Therapeutics Sarl has named the former Genmab Vice President Dr Patrick van Berkel as its Senior VP Research & Development.

Van Berkel brings in more than 20 years of experience in the biotech industry, in particular in developing antibody-based drugs. He served with Genmab for more than nine years in different divisions. Prior to Genmab, Dr van Berkel worked for both Crucell and Pharming Technologies. He authors nine antibody patents and has published more than 30 scientific papers during his industry career. Van Berkel predicts an „explosion in ADC therapies  in the coming decade“.

03.08.2012 Belgian Amakem NV appointed Maarten van Geffen as new head of CMC and Operations in mid-July.

Van Geffen brings nearly 25 years international management experience in pharmaceutical development to Amakem, a kinase platform company focusing on ophthalmology. Previously, he was Director of Product Development at Shire-Movetis NV and responsible for the pharmaceutical development of the GI early and late phase products and was the CMC (Chemistry, Manufacturing & Controls) lead for due diligence of early phase and late phase small and large molecule products. Prior to working at Shire-Movetis NV, van Geffen held several positions as Director of CMC Regulatory Affairs at Barrier Therapeutic NV, Centocor BV, and Janssen Research Foundation.

07.08.2012 German biotech Wilex AG will change its executive management board. Chief Financial Officer Peter Llewellyn-Davies has to leave the company upon the expiration of his six year contract on September 1st. Jan Schmidt-Brand will take over.

Schmidt-Brandt is currently the Managing Director of Wilex's subsidiary Heidelberg Pharma GmbH. He was the CEO of Heidelberg Pharma AG until the company was acquired by Wilex. From 1997 to 2001, he was Managing Director of the Austrian BASF-Pharma subsidiary, EBEWE Arzneimittel GmbH, where his responsibilities included finance and controlling. Prior to this, he held several positions at the BASF Group for a total of eight years, most recently as an executive in the central tax department. Schmidt-Brand is a member of the Board of BioDeutschland and Head of the Finance and Tax working group. Llewellyn-Davies will pursue new activities but continues to act as an advisor for the company. He will fully manage and complete the capital measure announced by Wilex on August 3. “Mr Llewellyn-Davies has made important contributions to the development of Wilex since joining the company prior to its IPO in 2006. We would like to thank him very much for his collaboration, which was both constructive and successful, and wish him great success in realizing his objectives”, said Professor Christof Hettich, Chairman of the Supervisory Board.

14.08.2012 Italian IT expert Massimiliano Claps is the new EMEA research director for the Government and Health Insights department, announced the International Data Corporation (IDC).

Claps will lead IDC’s ongoing research programmes for the government and healthcare sectors in Europe, the Middle East, and Africa. He will also be responsible for analysing key trends related to IT strategies and spending in European governments and healthcare provider organisations. 

After graduating in business administration at Milan’s Bocconi University, Claps worked as a junior consultant for the Monitor Group where he advised major multinationals in the food and beverage, construction, media and telecoms, and pharmaceutical industries. His career in the IT sector began with his first stint at the IDC: Between 2002 and 2007 he worked for the EMEA Government and Health Insights business as well as for a year with IDC Canada to fast-track their government research. Max Clap’s latest assignment was to head the government team of one of the world’s leading information technology research and advisory companies, Gartner, Inc. 

21.08.2012 Horizon Discovery appointed Richard Vellacott as its new Chief Financial Officer. Vellacott has over 15 years’ experience in working with life sciences companies, from start-ups to global pharmaceuticals.

Prior to joining Horizon, he was Vice President Finance at CSR plc. During his time at CSR, Vellacott had worldwide responsibility for finance, making significant contributions to the transformational acquisition and integration of NASDAQ-listed Zoran Corp., product portfolio management, R&D budgeting and business investment. Before this, he was a Director in Deloitte’s life sciences practice, where he specialised in capital market transactions including IPOs, M&A and fundraising on both the UK and the US markets. Horizon Discovery Limited (“Horizon”) is a leading provider of research tools to support the development of personalised medicines. 

17.08.2012 Dr. Ilka Diester has received the prestigious Boehringer Ingelheim FENS Research Award. The Frankfurt-based neurobiologist got a price money of €25,000 at the Forum of the Federation of European Neuroscience Societies in Barcelona.

The award was dedicated to her research at Ernst-Strüngmann-Institut where she and her team analyse sensomotoric circuits with help of optogenetic and electrophysiological tools. Their research aims at developing neuroprotheses which can compensate neuronal functional disorders. The price is sponsored by the FENS and Boehringer.

04.09.2012 Portuguese API specialist Hovione (Loures) has named Dr. Conrad Winters as new Drug Product Development Director.

Dr Winters was previously with Merck in the USA and Canada and most recently with Xenon Pharmaceuticals Inc., where he held the position of Senior Director, Compound Properties Group. The pharmacist brings 18 years of experience in the pharmaceutical industry with a focus on managing the development of compounds from lead candidate optimisation to NDA submission and commercialisation. He has extensive experience in rational formulation design, based on fundamental understanding of material properties and the adaptation of particle properties to effect improved bioperformance. Winters has led cross functional global teams charged with the development of priority new chemical entities. He has contributed to and prepared documentation in support of many successful regulatory submissions.

31.08.2012 Swiss drug giant Roche AG has filled the leadership gap at its pharma division after its former head Pascal Soriot left the company to become CEO of British-Swedish pharma major AstraZeneca.

From 1 September, Daniel O’Day, currently COO at Roche Diagnostics, will step in. O’Day will be succeeded by Roland Diggelmann, currently Head of the Asia-Pacific Region within Roche Diagnostics who has been appointed as a new member of the Executive Committee by the Board of Directors. Daniel O’Day began his career in 1987 at Roche in the U.S. Pharmaceuticals organisation in Sales and Marketing. Following that, he held various positions in Roche Pharma in Switzerland, Japan, and Denmark. In 2006, O’Day joined Roche Diagnostics and became Head of the business area „Molecular Diagnostics“. On January 1 2010 he was appointed Chief Operating Officer for Roche’s global diagnostics business.

29.08.2012 Dr Decio L. Eizirik, Director at the University libre de Brussels (ULB), has been awarded the 2012 Albert Renold Prize of the European Association for the Study of Diabetes (EASD).

The prize is the most important international award in the field of pancreatic islets, and recognises "an individual's outstanding contribution to the advancement of knowledge in the field of research in the islets of Langerhans". Professor Eizirik and his colleagues at the Laboratory of Experimental Medicine at ULB have been investigating the molecular pathways involved in immune-induced beta cell impairment and apoptosis in type 1 diabetes (T1D). His research led to fundamental concepts such as the dialogue between the immune system and beta cells that trigger and amplify islet inflammation (insulitis) and progressive beta cell death by apoptosis. By using functional genomics and bioinformatics tools he and his group have clarified the cytokine-regulated gene networks that define beta cell outcome, including the recent discoveries of the role of endoplasmic reticulum stress and alternative splicing in this process, and the identification of the mitochondrial pathways that ultimately trigger beta cellapoptosis.By proposing that the beta cell is an active player in processes leading to its survival or death in T1D, Dr Eizirik changed the prevailing view in the field and identified several potential targets for therapy aiming at protecting beta cells in early diabetes.

Vorherige Seite3/6Nächste Seite

Print Magazine

Event Video

All videos

Events

All Events

Stock list

All quotes

TOP

  • VITA 344.32 EUR6.67%
  • MORPHOSYS74.44 EUR4.04%
  • STRATEC BIOMEDICAL39.84 EUR3.94%

FLOP

  • CYTOS0.16 CHF-5.88%
  • CO.DON2.75 EUR-3.17%
  • ADDEX3.30 CHF-2.94%

TOP

  • BIOFRONTERA2.90 EUR31.2%
  • VITA 344.32 EUR8.0%
  • BB BIOTECH157.70 EUR7.3%

FLOP

  • PAION2.24 EUR-30.0%
  • CYTOS0.16 CHF-27.3%
  • MAGFORCE5.90 EUR-17.5%

TOP

  • SANTHERA85.50 CHF2335.9%
  • CO.DON2.75 EUR192.6%
  • PAION2.24 EUR163.5%

FLOP

  • CYTOS0.16 CHF-95.8%
  • THERAMETRICS0.08 CHF-42.9%
  • 4SC0.97 EUR-42.6%

No liability assumed, Date: 23.10.2014


Current issue

All issues

Product of the week

Products